TheEdgeResearch
Home / Stocks / LBTSF

Almirall, S.A. (LBTSF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$15.35 ▼ -0.78%
Market Cap
$3.34B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.18
52-Wk Range
9.01-15.47
CEO
Carlos Gallardo Piqué
Country
ES
Currency
USD

Almirall, S.A. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Barcelona, ES. The stock last traded at $15.35, down 0.78% on the session, giving a market capitalisation of $3.34B. On trailing twelve-month figures it carries a trailing P/E of 31.57, a net margin of 5.1%. Its beta of 0.18 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
31.57
Price / Sales
1.62
Price / Book
1.49
EV / EBITDA
4.74
Gross margin
74.0%
Operating margin
8.5%
Net margin
5.1%
Return on equity
—
Debt / equity
0.24
Current ratio
2.31
Dividend yield
1.8%
Payout ratio
5.3%
Company profile
Exchange
Other OTC
Employees
2,026
IPO date
2012-08-03
Headquarters
Barcelona, ES
About Almirall, S.A.

Almirall, S.A. is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of dermatology-focused pharmaceuticals. Its operations span Europe, the United States, and various international markets. The company provides treatments targeting a wide array of skin conditions, including actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and several orphan indications. Beyond its core dermatological focus, Almirall also extends its offerings to other therapeutic areas, such as cardiovascular, musculoskeletal, respiratory, and neurological disorders; alimentary tract and metabolic conditions; systemic anti-infectives; genitourinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Among its key products are Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. The company fosters numerous collaborations and strategic alliances with partners such as Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. Originally established as Laboratorios Almirall, S.A. in 1943, the company adopted its current name, Almirall, S.A., in May 2009, and is headquartered in Barcelona, Spain.

Comparable companies

Almirall, S.A. is most often compared with the following Healthcare names:

ARSUFCASBFCHSYFCURLFDMPHFGTBIFHTSUFSHPHFTSMRFVTRLY
More research on LBTSF
LBTSF technical analysis LBTSF TheEdge Score Compare against peers
Open full interactive analysis & DCF →